3 {. S& e' Y* [* e& L/ N, Z+ H临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:: S& ?7 t5 S* _5 @" C
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.( v' ]- q q N http://www.ncbi.nlm.nih.gov/pubmed/22968184' O' z! s! x, S# L E0 P